



Brian Andrew Jonas, M.D., Ph.D.

Philosophy of Care

Dr. Jonas believes in high quality, personalized, cutting edge, innovative, and compassionate care of his patients. Dr. Jonas has clinical trials that can offer new and progressive treatment options for his patients. Dr. Jonas believes in a team-based approach to patient care, utilizing expertise of nurse practitioners, nurses, pharmacists, social workers, and consultants to provide complete care for his patients.

Clinical Interests

Dr. Jonas is a specialist in hematologic malignancies, BMT and cellular therapy. His main clinical interests include: acute myeloid leukemia, myelodysplastic syndromes (MDS), acute lymphoblastic leukemia, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes, CML, other myeloid malignancies.

Research/Academic Interests

Dr. Jonas specializes in acute myeloid leukemia, myelodysplastic syndromes (MDS), acute lymphoblastic leukemia, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes, CML, other myeloid malignancies. Dr. Jonas directs the acute leukemia and MDS research efforts at UCDCCC. He has built a thematic clinical and translational research program in AML, MDS and ALL with an emphasis on early drug development and biomarker development and with a goal of having a clinical trial to offer each patient. He is also Chair of the UCDCCC Hematologic Malignancies Disease Team and is Chair of the UCDCCC Data and Safety Monitoring Committee.

Title Associate Professor of Medicine (Clin X)

Specialty Leukemia, Bone Marrow Transplant

Department [Internal Medicine](#)

Division [Malignant Hematology/Cellular Therapy and Transplantation](#)
Hematology and Oncology

Center/Program Affiliation [UC Davis Comprehensive Cancer Center](#)

Address/Phone UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817
Phone: 916-734-5959

Additional Phone Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education M.D., UC Davis School of Medicine, Davis CA 2007
Ph.D., Biochemistry and Molecular Biology, UC Davis School of Medicine, Davis CA 2007
B.A., Molecular & Cell Biology, History, UC Berkeley, Berkeley CA 1999



Brian Andrew Jonas, M.D., Ph.D.

Internships	Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2007-2008
Residency	Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2008-2009
Fellowships	Hematology and Oncology, Stanford University School of Medicine, Stanford CA 2009-2013
Board Certifications	American Board of Internal Medicine American Board of Internal Medicine, Hematology American Board of Internal Medicine, Medical Oncology Drug Enforcement Administration Registration Medical Board of California, Physician and Surgeon License
Professional Memberships	American Association for Cancer Research American College of Physicians, Fellow American Medical Association American Physician-Scientist Association American Society of Clinical Oncology American Society of Hematology Association of Northern California Oncologists (ANCO) California Cancer Consortium California Medical Association Myelodysplastic Syndrome Foundation Sierra Sacramento Valley Medical Society Southwest Oncology Group (SWOG) TheMednet UC Davis Comprehensive Cancer Center UC Hematologic Malignancies Consortium
Honors and Awards	Highest Overall Accrual, UC Davis Comprehensive Cancer Center, 2020, 2021 NCI Cancer Center Support Grant Supplement Cancer Clinical Investigator Team Leadership Award, 2020 Highest Accrual, Hematologic Malignancies Clinical Trials, UC Davis Comprehensive Cancer Center, 2015, 2016, 2017, 2018, 2019, 2020, 2021 Named Sacramento Magazine Top Doctor Hematology/Oncology, 2018, 2019, 2020 Internal Medicine Outstanding Clinician Award, UC Davis Department of Internal Medicine, 2020
Select Recent Publications	Jonas BA, Wei AH, Recher C, DiNardo CD, Jang JH, Pratz K, Panayiotidis P, Montesinos P, Yeh SP,



Brian Andrew Jonas, M.D., Ph.D.

Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. *Am J Hematol*. 2022 May 14. doi:10.1002/ajh.26600. Epub ahead of print. PMID: 35567776.

Granowicz EM, Jonas BA. Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. *Onco Targets Ther*. 2022 Apr 21;15:423-436. doi:10.2147/OTT.S265637. PMID: 35479302.

Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, DiNardo CD, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. *Blood Cancer J*. 2022 Apr 20;12(4):71. doi:10.1038/s41408-022-00668-8. PMID: 35443742.

Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. *Am J Hematol*. 2022 Jun 1;97(6):E191-E194. doi:10.1002/ajh.26524. Epub 2022 Mar 18. PMID:35266185.

Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. *J Natl Compr Canc Netw*. 2022 Feb;20(2):106-117. doi:10.6004/jncn.2022.0009. PMID:35130502.

Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD,



Brian Andrew Jonas, M.D., Ph.D.

Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. *J Clin Oncol*. 2022 Mar 10;40(8):855-865. doi:10.1200/JCO.21.01546. Epub 2021 Dec 15. PMID:34910556.

DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. *Blood*. 2022 Feb 24;139(8):1135-1146. doi:10.1182/blood.2021010721. PMID:34543383.

Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. *Leuk Lymphoma*. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.

Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. *Expert Rev Hematol*. 2021 May;14(5):407-417. doi:10.1080/17474086.2021.1938533. Epub 2021 Jun 15. PMID:34076549.

© 2024 UC Regents